特发性肺纤维化患者肺康复与生存期相关

2021-11-09 小文子 MedSci原创

研究强化了IPF患者肺康复的益处。

特发性肺纤维化(IPF)患者肺康复的依从性和临床疗效,尤其是与慢性阻塞性肺病(COPD)患者相比,仍然不确定。发表在CHEST杂志的一项研究比较了接受相同监督、门诊肺康复计划的IPF患者与匹配COPD患者的反应。并确定完成肺康复或对肺康复的响应是否与IPF患者的生存期相关。

采用倾向评分匹配法,将纳入肺康复治疗的163例IPF患者与163例COPD对照患者进行1:1匹配。患者接受了为期8周的门诊项目,包括每周两次监督锻炼和教育课程以及额外的无监督家庭锻炼。

基线测量指标(T0)包括BMI,肺活量测定,增量往返步行试验(ISW),慢性呼吸系统问卷(CRQ)和虚弱状态(4m步态速度 < 1.0 m/s)。肺康复治疗完成后(T1)测量ISW、CRQ和总体变化评级问卷(GRCQ)。依从性定义为患者参加监督治疗次数。完成肺康复定义为参加肺康复后评估和至少8次监督治疗。肺康复状态定义如下:响应者:完成肺康复,并达到ISW变化的最小重要差异(≥38米);无响应者:完成肺康复但未达到ISW变化的最小重要差异(< 38米);未完成者:未完成肺康复。

研究人员比较了两组的肺康复完成率和疗效。记录IPF队列在肺康复出院后一年内的生存状态。Cox比例风险回归探索肺康复状况与全因死亡率之间的关系。

结果显示,两组的肺康复完成率相似(IPF:69%;COPD:63%;p=0.24)。肺康复治疗后,两组的ISW和CRQ均显著改善,但无组间差异。与COPD组的91%相比,IPF组有88%在肺康复后感觉“好多了”或“稍微好了一点”(p=0.45)。肺康复未完成(HR=5.62, 95%CI, 2.24-14.08)和无响应(HR=3.91, 95%CI, 1.54-9.93)与IPF一年内全因死亡率增加独立相关。根据肺康复状态分层,未完成者和无响应者在1年内死亡比例高于响应者(分别为40%、24%、10%;p < 0.01)。

这项真实世界研究数据表明,IPF患者对肺康复的完成率和响应程度与COPD患者组相似。IPF患者肺康复未完成和无响应与全因死亡率增加相关。进一步强化了IPF患者肺康复的益处。

原文出处:

Nolan CM, Polgar O, Schofield SJ, Patel S, Barker RE, Walsh JA, Ingram KA,George PM, Molyneaux PL, Maher TM, Man WDC, Pulmonary rehabilitation in idiopathic pulmonary fibrosis and COPD: a propensity matched real-world study, CHEST (2021), doi: https://doi.org/10.1016/ j.chest.2021.10.021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894829, encodeId=e2391894829f2, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Feb 24 02:57:38 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204279, encodeId=98c312042e921, content=<a href='/topic/show?id=7d71822e3e5' target=_blank style='color:#2F92EE;'>#肺纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82273, encryptionId=7d71822e3e5, topicName=肺纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 20 10:21:52 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058967, encodeId=5c95205896e18, content=<a href='/topic/show?id=9c4f821156f' target=_blank style='color:#2F92EE;'>#肺康复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82115, encryptionId=9c4f821156f, topicName=肺康复)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Mon Dec 27 21:57:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378313, encodeId=851e13e831337, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 11 04:57:38 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894829, encodeId=e2391894829f2, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Feb 24 02:57:38 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204279, encodeId=98c312042e921, content=<a href='/topic/show?id=7d71822e3e5' target=_blank style='color:#2F92EE;'>#肺纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82273, encryptionId=7d71822e3e5, topicName=肺纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 20 10:21:52 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058967, encodeId=5c95205896e18, content=<a href='/topic/show?id=9c4f821156f' target=_blank style='color:#2F92EE;'>#肺康复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82115, encryptionId=9c4f821156f, topicName=肺康复)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Mon Dec 27 21:57:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378313, encodeId=851e13e831337, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 11 04:57:38 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894829, encodeId=e2391894829f2, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Feb 24 02:57:38 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204279, encodeId=98c312042e921, content=<a href='/topic/show?id=7d71822e3e5' target=_blank style='color:#2F92EE;'>#肺纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82273, encryptionId=7d71822e3e5, topicName=肺纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 20 10:21:52 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058967, encodeId=5c95205896e18, content=<a href='/topic/show?id=9c4f821156f' target=_blank style='color:#2F92EE;'>#肺康复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82115, encryptionId=9c4f821156f, topicName=肺康复)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Mon Dec 27 21:57:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378313, encodeId=851e13e831337, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 11 04:57:38 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894829, encodeId=e2391894829f2, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Feb 24 02:57:38 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204279, encodeId=98c312042e921, content=<a href='/topic/show?id=7d71822e3e5' target=_blank style='color:#2F92EE;'>#肺纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82273, encryptionId=7d71822e3e5, topicName=肺纤维化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 20 10:21:52 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058967, encodeId=5c95205896e18, content=<a href='/topic/show?id=9c4f821156f' target=_blank style='color:#2F92EE;'>#肺康复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82115, encryptionId=9c4f821156f, topicName=肺康复)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Mon Dec 27 21:57:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378313, encodeId=851e13e831337, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 11 04:57:38 CST 2021, time=2021-11-11, status=1, ipAttribution=)]

相关资讯

Thorax:自动氧流量与恒定氧流量对COPD患者步行耐力的影响

使用ATOS可显著改善伴有低氧血症的重度COPD患者的步行耐受时间。

Eur Respir J:哮喘与COPD的异质性

哮喘和/或COPD患者中,医生的诊断和严重程度存在组内异质性,以及组间重叠。目前临床实践中的诊断和严重程度分类很难区分可能存在特定风险和治疗意义的临床表型。

横断面研究:重度哮喘和COPD护理者的需求和生活质量

重度哮喘和慢性阻塞性肺疾病(COPD)患者的生活质量(QoL)受损,导致护理需求增加。家庭照顾者在提供照顾方面发挥着独特的作用,但这可能对自己的生活质量不利。

ERJ:评估肺部疾病的肺动脉高压严重程度是改善结果的关键

管理与慢性肺病和/或缺氧 (PH-CLD) 相关的肺动脉高压 (PH) 患者仍然是肺血管医学中最具挑战性的领域之一。 它在 COPD 和间质性肺病 (ILD) 中的存在对症状和生存率产生负面影响,预示

ERJ:诱导型一氧化氮合酶的骨髓细胞特异性缺失可保护小鼠免受烟雾诱导的肺动脉高压

慢性阻塞性肺疾病 (COPD) 是全球五种主要死亡原因之一。 COPD的病理变化是由吸入有害物质如香烟烟雾引起的,包括慢性气道炎症和进行性肺泡破坏,导致慢性支气管炎和肺气肿。

CHEST:慢性阻塞性肺病患者的肺动脉高压--COMPERA研究结果公布

肺动脉高压 (PH) 是晚期 COPD 的常见表现; 它在特定人群(肺移植或减容手术的候选者)中的患病率约为 50%。